Rufinamide-d2

• Description :

  Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042) . Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome[1][2][3][4].

• CAS Number :

  [1129491-38-8]

• Product Name Alternative :

  CGP 33101-d2; E 2080-d2; RUF 331-d2

• UNSPSC :

  12352005

• Target :

  Isotope-Labeled Compounds; Sodium Channel

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Membrane Transporter/Ion Channel; Others

• Field of Research :

  Neurological Disease

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CN(C([2H])([2H])C2=C(F)C=CC=C2F)N=N1)N

• Molecular Formula :

  C10H6D2F2N4O

• Molecular Weight :

  240.21

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Chen JL, et.al. Inhibition of resurgent Na+ currents by rufinamide. Neuropharmacology. 2024 Apr 1;247:109835.|[3]White HS, et.al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49 (7) :1213-20.|[4]Suter MR, et.al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118 (1) :160-72.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported